- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.08. | US-China tensions offer new opportunity for APAC biotechs, report suggests | ||
| 05.08. | Gates Foundation invests $2.5bn in women's health-focused R&D | ||
| 05.08. | New US-EU trade deal on tariffs ends pharma's geopolitical immunity | ||
| 05.08. | CDMO insights podcast series: Our Experience is Your Strength | Episode #3 Clinical Forecasting, Packaging & Distribution | ||
| 05.08. | Pediatric research: how to fix a clinical trial system built for adults | ||
| 05.08. | SFDA approves Agios Pharma's Pyrukynd for thalassemia | ||
| 04.08. | Sandoz bolsters in-house biosimilar manufacturing with Evotec acquisition | ||
| 04.08. | Atombeat and BioDuro link for peptide drug discovery platform | ||
| 04.08. | Manufacturing issues at Novo facility disrupt Regeneron drug review | ||
| 04.08. | Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi | ||
| 04.08. | Europe's cannabis pharmaceuticals market matures amid cautious investment | ||
| 01.08. | Eli Lilly's Mounjaro shows cardiovascular gains, but analysts underwhelmed | ||
| 01.08. | Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics | ||
| 01.08. | Cell and gene therapy market outlook strong despite technical challenges | ||
| 01.08. | BeOne Medicines' BTK degrader gains EMA PRIME designation | ||
| 31.07. | George Tidmarsh to sub in as FDA CBER head following Prasad's shock exit | ||
| 31.07. | Targeting energy expenditure: the next wave of obesity drugs | ||
| 31.07. | Targeting energy expenditure: the next wave for obesity drugs | ||
| 31.07. | Dupixent sales spur Sanofi growth, but profits fall short | ||
| 31.07. | Dr Falk Pharma and Allianthera sign agreement for ATB102 | ||
| 31.07. | African countries plan shift to healthcare funding autonomy amid aid cuts | ||
| 31.07. | Meet the company on a mission to rewrite the cell therapy paradigm from South Texas | ||
| 31.07. | Viridian and Kissei to advance veligrotug and VRDN-003 in Japan | ||
| 30.07. | GSK's speciality medicines soar while generals drop, Q2 results reveal | ||
| 30.07. | Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEO |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .